 CAMBRIDGE, Mass., Sept. 27, 2022 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 12 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T. 